Navigation Links
AHIP Statement on H.R. 4626
Date:2/24/2010

Karen Ignagni, President and CEO of America's Health Insurance Plans (AHIP), released the following statement today on H.R. 4626

Washington, DC (Vocus) February 24, 2010 -- Karen Ignagni, President and CEO of America's Health Insurance Plans (AHIP), released the following statement today on H.R. 4626:

“In attempting to solve a problem that doesn’t exist, this legislation is the triumph of sound bites over substance. The Congressional Budget Office has said that passage of this legislation will do nothing to reduce health care costs. Moreover, according to the National Association of Insurance Commissioners, anti-competitive ‘activities are not permitted under the McCarran-Ferguson Act and are not tolerated under state law.’ Real reform means containing costs to ensure that health care is affordable for working families and small businesses. It’s time to clear the political hurdles that stand in the way of real cost containment.”

Additional information on the McCarran Ferguson Act

New AHIP Letter: Last week, AHIP sent a letter to Capitol Hill, which states: “The claim that McCarran-Ferguson allows insurers to engage in practices such as price fixing, market allocation, and bid rigging is incorrect and the types of activities the legislation proposes to address already are subject to federal and state antitrust laws.”

National Association of Insurance Commissioners letter (10/21/2009): “The potential for bid rigging, price fixing and market allocation is of great concern to state insurance regulators and we share your view that such practices are harmful to consumers and cannot be tolerated. However, we want to assure you that these activities are not permitted under the McCarran-Ferguson Act and are not tolerated under state law. Indeed, state insurance regulators actively enforce prohibitions in these areas.”

Congressional Budget Office analysis (10/29/09): “The analysis also takes into account the provisions of section 262 of Division A regarding the application of federal antitrust laws to health insurers. CBO estimates that implementing those provisions would have no significant effects on either the federal budget or the premiums that private insurers charged for health insurance.”

Congressional Research Service analysis (8/31/2009): “Given the courts’ narrowing definition of the ‘business of insurance,’ they would not be likely, in any event, to find such activities as market allocation, tying, or monopolization protected by McCarran-Ferguson from the application of the antitrust laws.”

What Others Are Saying About McCarran-Ferguson:

Los Angeles Times: “Lawmakers are expected to pass a bill this week that would repeal the federal antitrust exemption that insurance companies have enjoyed since 1945 -- a move that makes for little more than a good sound bite…Removing the exemption won't do much to boost competition or spark a price war among insurers, however. (The Congressional Budget Office said that a similar proposal in the House's comprehensive healthcare bill would have no significant effect on premiums because state regulators already require insurers to price their coverage competitively.)” (Los Angeles Times, Back to the drawing board, 02/08/2010)

Paul Ginsburg, Center for Studying Health System Change: “‘I don't think this will have much effect. This is strictly political posturing.’…In fact, Ginsburg said, insurers already are prohibited from colluding to raise prices and from merging at will. They can, however, pool information about risks, and it can be argued that that helps them manage ways of controlling costs and even rates.” (McClatchy, Analysts: Stripping health insurers' antitrust protection won't affect consumers much, 02/07/2010)

Kaiser Health News: “…many antitrust experts say that ending the exemption -- by repealing the 1945 McCarran-Ferguson Act -- wouldn't significantly increase competition or reduce premiums.” (Kaiser Health News, The Antitrust Exemption For Health Insurers: Meaningful Or Not?, 02/08/2010)
Scott Harrington: “It might sound good, but I can think of very few things in the bill that would be
less consequential for consumers of health insurance.” (Kaiser Health News, The Antitrust Exemption For Health Insurers: Meaningful Or Not?, 02/08/2010)

CQ: “…bill supporters have little evidence to support claims that the antitrust exemption leads to higher costs. In fact, their statements in support of the bill sometimes suggest the opposite.” (CQ, House Democrats Push Bill to Eliminate Insurance Antitrust Exemption, 02/05/2010)

Ezra Klein: “On the other hand, since it doesn't matter much, and it's good politics either way, Democrats may as well go after it. They just shouldn't fool themselves into thinking they've actually done anything useful when they've finished.” (The Washington Post, Ezra Klein, A primer on the antitrust exemption for insurers, 02/08/2010)

Contact:
Robert Zirkelbach
202-778-8493

###

Read the full story at http://www.prweb.com/releases/AHIP_Statement/HR_4626/prweb3649054.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Court Orders Reinstatement of Vital, Cost-Saving Treatment for Children With Autism
2. Catholic Health Association Statement on February 25 Health Reform Summit
3. AHIP Statement on the Status of Health Care Reform
4. Statement from Larry Minnix, President & CEO, American Association of Homes and Services for the Aging, on President Obamas Health Care Reform Proposal
5. Pelosi Statement on President Obamas Health Insurance Reform Proposal
6. Pelosi Statement on Additional Aid to States In Medicare Part D Payments
7. Statement from Lawrence Massa, CEO and President, Minnesota Hospital Association
8. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
9. PolicyLink CEO Angela Glover Blackwell Released the Following Statement on First Lady Michelle Obamas Childhood Obesity Initiative
10. AHIP Statement on New Health Spending Projections
11. Statement From IHA President Maryjane A. Wurth on Illinois Supreme Court Medical Liability Ruling
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
AHIP Statement on H.R. 4626 
(Date:2/27/2017)... ... , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme and ... for Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) dismiss ... compiled into a single volume a compelling argument that the disease does exist in ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top five ... genders. And the need for advanced services is growing. , Project WE vs ... program, in collaboration with their non-profit partners in their fight against cancer and in ...
(Date:2/26/2017)... New York (PRWEB) , ... February 26, 2017 ... ... baby products for wholesale distribution in North America, today announced it would be ... sites. The company, which prides itself on crafting quality and unique baby clothing/feeding ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in persons with a specific LRRK2 mutation, according to a study released today ... have provided evidence of a link between pesticides and incidence of sporadic PD ...
(Date:2/24/2017)... Princeton, NJ (PRWEB) , ... February 24, 2017 ... ... organization that provides business development, education, networking and recognition opportunities as well as ... at Bell Works in Holmdel, NJ on February 23. The Council's Innovation ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... SILVER SPRING, Md. , Feb. 23, 2017 ... today allowed marketing of the PhenoTest BC Kit, ... first test to identify organisms that cause bloodstream ... organism is likely to respond to (antibiotic sensitivity). ... it takes to provide this important information, which ...
(Date:2/24/2017)... Australie, le 24 février 2017 ITL Limited, ( ASX : ... innovante, est ravie d,annoncer les excellents résultats semestriels clos ... précédente correspondante. Une présentation complète « Résultats et mise à ... ici . Faits marquants ... (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
Breaking Medicine Technology: